Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
Conditions: Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-cell Lymphoma Intervention: Biological: RC19D2 cell injection Sponsor: Beijing Yongtai Ruike Biotechnology Company Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials